Reported about 3 hours ago
Danish pharmaceutical company Lundbeck has announced its acquisition of Longboard Pharmaceuticals for $2.6 billion. This acquisition aims to enhance Lundbeck's portfolio, specifically focusing on its epilepsy drug treatment pipeline. Experts provide additional insights into the implications of this deal.
Source: YAHOO